Tuesday's Small-Cap Winners & Losers
Small-cap stocks trailed the rest of the market Tuesday, but among these, a few health care names excelled nonetheless.
For instance, New Jersey's Pharmos (PARS) was one of today's best-performing stocks overall, surging 37.3% after its cannabinor treatment achieved the primary endpoint of a phase IIa trial. The cannabinoid -- a synthetic compound chemically related to marijuana -- yielded statistically significant results in post-operative pain relief. Shares gained 56 cents to $2.06.
Symbion (SMBI) vaulted 17.9% to $22.43 after the Nashville, Tenn., surgical-facilities operator agreed to sell itself to private-equity firm Crestview Partners for $22.35 a share. The $637 million deal (including debt assumption) should close in the third quarter. And biotech Halozyme Therapeutics (HTI) shares leapt 11.1% to $9.94 after the company agreed to sell 3.5 million newly minted company shares to New River Management at a premium of $9.17 apiece.
Elsewhere, California's Irvine Sensors (IRSN) surged 27.3% to $1.68 after its Optex Systems unit received more than $9 million in new orders for its military optical systems. These should begin shipping in the second half of fiscal 2007. Firearms maker Sturm, Ruger & Co. (RGR) climbed 11.5% to $13.44 after first-quarter income ratcheted up more than sevenfold from last year to 36 cents a share, or $8.1 million.
Volterra Semiconductor (VLTR), meanwhile, gained 10.8% to $16.44 after first-quarter earnings added a penny on last year to 7 cents a share, squaring with Wall Street targets, according to Thomson Financial. House of Taylor Jewelry (HOTJ), based in West Hollywood, Calif., brought in more than six times higher fourth-quarter 2006 sales year over year. Shares leapt 7.6% to $2.40.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV